This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).
- Generic Name
- Canrenone
- DrugBank Accession Number
- DB12221
- Background
Canrenone has been used in trials studying the diagnostic of Heart Failure.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Canrenone (DB12221)
- Weight
- Average: 340.4559
Monoisotopic: 340.203844762 - Chemical Formula
- C22H28O3
- Synonyms
- Canrenone
- External IDs
- SC-9376
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Canrenone may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy. Acebutolol The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Canrenone. Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Canrenone. Acemetacin The therapeutic efficacy of Canrenone can be decreased when used in combination with Acemetacin. Acetaminophen Canrenone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. Acetyldigitoxin Canrenone may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Canrenone which could result in a higher serum level. Aclidinium Canrenone may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy. Acrivastine Canrenone may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy. Acyclovir Canrenone may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- C03DA03 — Canrenone
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as steroid lactones. These are sterol lipids containing a lactone moiety linked to the steroid skeleton.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid lactones
- Direct Parent
- Steroid lactones
- Alternative Parents
- 3-oxosteroids / Cyclohexenones / Gamma butyrolactones / Tetrahydrofurans / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- 3-oxosteroid / Aliphatic heteropolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Cyclohexenone / Gamma butyrolactone / Hydrocarbon derivative / Ketone
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 78O20X9J0U
- CAS number
- 976-71-6
- InChI Key
- UJVLDDZCTMKXJK-WNHSNXHDSA-N
- InChI
- InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1
- IUPAC Name
- (1R,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-2,3,3a,3b,7,8,9,9a,9b,10,11,11a-dodecahydrospiro[cyclopenta[a]phenanthrene-1,2'-oxolane]-5',7-dione
- SMILES
- [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C
References
- General References
- AIFA Product Information: Luvion (canrenone) for oral/intravenous administration [Link]
- External Links
- Human Metabolome Database
- HMDB0003033
- PubChem Compound
- 13789
- PubChem Substance
- 347828500
- ChemSpider
- 13192
- 1982
- ChEBI
- 135445
- ChEMBL
- CHEMBL1463345
- ZINC
- ZINC000003881648
- Wikipedia
- Canrenone
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Hypertension, Essential Hypertension 1 4 Unknown Status Treatment Paroxysmal Atrial Fibrillation (PAF) 1 3 Completed Diagnostic Heart Failure 1 2 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome Caused by COVID-19 / Coronavirus Disease 2019 (COVID‑19) 1 Not Available Completed Not Available Cardiac Heart Failure Patients 1 Not Available Completed Not Available Primary Aldosteronism Due to Aldosterone Producing Adenoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule 100 MG Capsule 50 MG Tablet Oral 50 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0042 mg/mL ALOGPS logP 2.79 ALOGPS logP 3.6 Chemaxon logS -4.9 ALOGPS pKa (Strongest Basic) -4.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 43.37 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 97.48 m3·mol-1 Chemaxon Polarizability 38.67 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at October 20, 2016 21:39 / Updated at May 21, 2021 10:22